Prima BioMed (NASDAQ:IMMP) Stock Price Passes Below 50-Day Moving Average – Here’s What Happened

Prima BioMed Ltd (NASDAQ:IMMP)’s stock price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.45 and traded as low as $0.3550. Prima BioMed shares last traded at $0.3703, with a volume of 225,835 shares.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Maxim Group cut shares of Prima BioMed from a “buy” rating to a “hold” rating in a research report on Friday, March 13th. Robert W. Baird cut shares of Prima BioMed from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $7.00 to $1.00 in a research report on Friday, March 13th. Wall Street Zen upgraded shares of Prima BioMed to a “hold” rating in a research report on Saturday, April 18th. Finally, Citizens Jmp cut shares of Prima BioMed from an “outperform” rating to a “market perform” rating in a research report on Friday, March 13th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $5.50.

Prima BioMed Trading Up 1.8%

The company’s 50-day moving average price is $0.45 and its two-hundred day moving average price is $1.67.

Institutional Investors Weigh In On Prima BioMed

An institutional investor recently raised its position in Prima BioMed stock. Jane Street Group LLC increased its holdings in Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 51,574 shares of the biotechnology company’s stock after purchasing an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent SEC filing. 2.32% of the stock is currently owned by institutional investors.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.